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Summary We examined 46 non-small-cell lung carcinomas (NSCLCs) for the presence of p53 mutations in exons 4-9, positive p53
immunostaining and loss of heterozygosity (LOH) in the TP53 locus. p53 mutations were detected in 13 tumour samples (28.3%), whereas
overexpression of the p53 protein was found in 30 of 45 (67%) samples. Allelic loss was found in 9 of 38 (23.6%) informative cases. The
statistical analysis revealed no significant correlation between p53 mutations and clinicopathological data, although mutations appear to
occur more frequently in squamous cell carcinomas (7 of 18) than in adenocarcinomas (2 of 15). All but three individuals in this study group
smoked. In contrast to previous reports, we found a higher prevalence of GC-AT transitions than of GC-TAtransversions, as expected in a
smoking population. A trend was found between p53-positive immunostaining and a history of heavy smoking (76-126 pack-years) and was
inversely correlated with allelic deletion (LOH) at the TP53 locus. Eight of the 12 NSCLCs containing p53 mutations also had concomitant p53
overexpression, and it is of specific note that three of the four tumours containing p53 'mutations' with no overexpression of the p53 protein
had either insertions or deletions in the p53 gene. No correlation was found between p53 mutations and fractional allele loss or ras mutations.
p53 mutations in this Merseyside population in the UK do not appear to be as common as in other reports for NSCLC and exhibit
predominance of GC-AT transitions preferentially at non-CpG sites, suggesting that other carcinogens in addition to those in tobacco smoke
may be involved in NSCLC in the Merseyside area of the UK.
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Lung cancer is one of the major causes of death in the Western
world. Small-cell lung carcinomas (SCLC) account for approxi-
mately 25% of all lung tumours and non-small-cell carcinomas
(NSCLCs) constitute the remaining 75% (Whitehouse, 1994).
Lung cancer development is strongly related to environmental
agents, and smoking appears to be responsible for the majority
of the cases. Lung cancer is considered to be the major cause of
death among smokers in the United States (Shopland et al, 1991).
Cigarette smoke contains anumberofcarcinogens, such as benzo-
[a]pyrene, which may act in the initiation and/or promotion ofthe
disease (DeMarini, 1983).
During the last decade, a number of the known oncogenes and
tumour-suppressor genes have been shown to be altered in lung
tumours (Field et al, 1994). The p53 gene encodes for a 53-kDa
nuclear phosphoprotein which functions as a transcription factor
and it is implicated in the regulation of the cell cycle and subse-
quently in growth control. p53 acts as a tumour-suppressor gene,
arresting cells in the GIG1 phase whenever DNA is damaged to
give more time for the cell's DNA repair mechanism to function,
and, if unsuccessful, leads cells to apoptotic death (Levine et al,
1991; Lane, 1992; Yin et al, 1992).
The p53 gene has been found to be mutated in a large range
of human tumours (Hollstein et al, 1991; Greenblatt et al, 1994;
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Sidransky and Hollstein, 1996). Many international research groups
have contributed to the identification of p53 mutations and in a
number ofcases have correlated the presence ofp53 mutations with
stage, histology, prognosis and exposure to certain environmental
agents. Mutagens can produce specific base substitutions at certain
sites, and a mutation spectrum analysis may provide information
about the origins of mutations that give rise to human tumours. A
recent review of the published data on p53 mutations in human
tumours worldwide led to a number of hypotheses concerning the
role ofp53 in carcinogenesis (Greenblatt et al, 1994).
Lung tumours have been shown to contain various genetic aber-
rations within thep53 gene, including point mutations, insertions,
deletions and loss ofheterozygosity at the TP53 locus (Chiba et al,
1990; Lehman et al, 1991; Sameshima et al, 1992; Mitsudomi et
al, 1992, 1993; Suzuki et al, 1992; Lohman et al, 1993; Takeshima
et al, 1993; Westra et al, 1993; Carbone et al, 1994; Zheng et al,
1994). With respect to point mutations, GC-.TA transversions
have been shown to occur more frequently in smokers than in
non-smokers with lung cancer and may be the result of specific
carcinogenic agents present in tobacco smoke, such as benzo-
[a]pyrene (Greenblatt et al, 1994; Husgafuel-Pursianen et al, 1995;
Ramet et al, 1995).
In the present study, we have examinedp53 status in 46 patients
with NSCLC for the presence of mutations in exons 4-9, expres-
sion ofthep53 gene and allelic loss in the TP53 locus. All patients
live within Merseyside, UK, where the incidence of the disease
is Youngson and Williams, 1995 among the highest in Europe,
especially in women (Williams, 1992).
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Figure 1 Example of screening for point mutations in exon 5 of p53 by
SSCP analysis. PCR products were denatured and run through an 8% native
polyacrylamide gel, and the gels were visualized by silver staining. Bands
with mobility shifts are indicated by arrows
MATERIALS AND METHODS
Tissue samples
Tumours were obtained from patients undergoing lung resection
for bronchial tumours at the Cardiothoracic Centre, Liverpool,
UK. All patients were Caucasians, and all but three were smokers.
After resection the tumours were snap frozen and stored at -70'C.
Forty-six NSCLC specimens were analysed from 28 men and 18
women, of which 15 were adenocarcinomas, seven adenosquam-
ous, 18 squamous, three large-cell, one neuroendocrine, one carci-
nosarcoma and one sarcomatoid carcinoma.
_mmunohistochemistry
The immunohistochemical demonstration of p53 protein was
performed using a standard ABC technique on formalin-paraffin-
processed sections. The antigen was unmasked by microwaving in
citrate buffer pH 6.0 for 15 min at full power in a 650-W
microwave oven. The primary antibody, DO-I monoclonal anti-
body, was used at a concentration of 1:50 for 2 h at room tempera-
ture. The secondary antibody (Vector elite standard kit) was used
at a 1:100 for 30 min at room temperature. Diaminobenzidene was
used as the chromogen. The slides were scored as a percentage of
positive cells per field (WP and JRG).
DNA extraction and PCR
Tumour tissues were microdissected before DNA extraction,
which was undertaken with Nucleon II (Scotlab, Coatbridge, UK).
The oligonucleotides used for the polymerase chain reaction
(PCR) amplification of the p53 exons and the thermal profile
of the amplification have been described previously (Lehman
et al, 1991). The reaction mixture contained 16 mm ammonium
sulphate, 67 mt Tris-HCl pH 8.8, 0.1% Tween-20, 100 lM
dNTPs, 0.4 FtM ofeach primer, 2 mm magnesium chloride and 0.5
units ofBiopro DNA polymerase (Bioline, London, UK).
SSCP analysis
Single-strand conformation polymorphism (SSCP) analysis was
undertaken as follows: 2-5 tl ofthe PCR product was mixed with
10 itl ofdenaturing solution, which consisted of 50% formamide,
50 mm sodium hydroxide, 1 mM EDTA, 0.1% bromophenol blue
and 0.1% xylene cyanol FF. Samples were then heated at 95°C for
3 min, chilled on ice and loaded onto an 8-10% native polyacryl-
amide gel containing 5% glycerol. Gels were run at 10°C and,
after electrophoresis, the bands were visualized by silver staining.
Sequencing
DNA samples that showed altered mobility in SSCP analysis were
amplified using a 5' biotinylated upstream primer. The strands of
the PCR product werethen separated using streptavidin-conjugated
Dynabeads M-280 (Dynal, Brombrough, UK). Sequencing reaction
was performed using Sequenase version 2.0 kit (Amersham Life
Table 1 Sequence analysis results for mutations in the p53 gene in lung tumours
Patient Age Sexe Histopathology p53 p53 mutation Sequence AA Allelicc
no. (years) expressionb change change imbalance
Exon Codon at TP53
3 67 M Squamous No Data 5 136 caa > taa Gin > stop LOH
18 65 M Squamous ++ 5 131 aac > gac Asn > Asp No LOH
138 gcc > gtc Ala > Val
25 69 M Squamous +++ 7 248 cgg > cag Arg > Gln No LOH
27 57 M Squamous +++ 7 247 aac > aat Silent No LOH
41 65 M Squamous ++ 5 158 cgc > ccC Arg > Pro No LOH
43 65 F Squamous +++ 8 273 cgt > cat Arg > His No LOH
44 64 M Squamous - 8 294 gag > tag Glu > stop No LOH
19 64 F Adenosquamous - 8 297 3-bp insertion His > Gln-Ser NI
21 58 F Adenosquamous - 7 229-235 19-bp deletion Truncation NI
34 73 M Adenocarcinoma ++ 7 245 ggc > tgc Gly > Cys Ml
49 59 M Adenocarcinoma +++ 8 268 4-bp deletion Frameshift No LOH
28 72 F Large cell ... 7 258 gaa > aaa Glu > Lys No LOH
52 67 M Large cell - 5 intron 4 1-bp insertion Splicing?
157 1-bp deletion Frameshift LOH
159 gcc > gtc Ala > Val
aM, male; F, female. b(_) negative staining, (++) or (+++) positive staining. cLOH, loss of heterozygosity; NI, non-informative; Ml, microsatellite instability. All but
one patient (19) with a mutation in the p53 gene had a history of smoking.
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Figure 2 Sequence analysis of exon 8 of p53 from patient no. 19 showing a
GAG insertion which distorts the whole sequence upstream
Sciences, Little Chalfont, UK). Reaction products were elec-
trophoresed through a 6% denaturing polyacrylamide gel. Gels
were then fixed, dried and exposed to Kodak XAR-50 films at
room temperature.
Loss of heterozygosity at the TP53 locus
The LOH analysis ofthe TP53 (17pl3.1) locus was undertaken with
oligonucleotide primers purchased from Research Genetics
(Huntsville, USA). The amplification reaction mixture contained
16 mm ammonium sulphate, 67 mi Tris-HCl pH 8.8, 0.1% Tween-
20, 200 [tM dNTPs, 0.4 FtM ofeachprimer, 2 mmmagnesiumchloride
and0.5 units Biopro DNApolymerase. The amplification parameters
were 940C for 30 s, 59°C for 30 s and 720C for 30 s. Twenty-eight
cycles were performed. PCR products were analysed by elec-
trophoresis on 10% polyacrylamide gels. Bands were visualized
using silver staining (Field et al, 1995, 1996; Neville et al, 1996).
Statistical analysis
In order to find any correlations between the presence ofmutations
and the clinicopathological data, the Fisher's exact test was
employed, using the SAS software for PCs.
Figure 3 Sequence analysis of exon 5 of p53 in a DNA sample from patient
no. 18, displaying a C-.T transition, as indicated by an arrow
RESULTS
We examined 46 NSCLCs and their normal adjacent tissue samples
for aberrations in the p53 gene. Initially, we screened all of the
samples for p53 mutations using the SSCP technique (Figure 1).
Positive tumours were then subjected to direct sequencing to
confirm the mutation and identify its exact nature. Sequence
analysis revealed 16 mutations in 13 samples (28.3%), including
three deletions (one 1-bp deletion, one 4-bp deletion and one 19-bp
deletion), two insertions (one 3-bp insertion and one 1-bp inser-
tion) and 11 base substitutions (examples of such mutations are
shown in Figures 2 and 3). The base substitutions consisted offour
C-T transitions, two G-T transversions, three G- A transitions,
one A- G transition and one G- C transversion. Six samples were
found to carry a polymorphism in exon 4, codon 72 (CGC-.CCC,
Arg-.Pro).p53 mutations were found in exons 5, 7 and 8 and, with
the exception of one 1-bp deletion, all were located in the coding
regions (Table 1). No mutations were found in adjacent normal
tissue samples.
In order to eliminate the possibility of missing any of the p53
mutations because of SSCP false negatives, for each exon we
sequenced 10 DNA samples picked randomly from those that had
demonstrated no abnormality in SSCP analysis. No sequence
abnormalities were detected in these analyses. In all SSCP-
positive findings the mutations were reconfirmed by sequencing
PCR products amplified by a separate aliquot ofthe DNA sample.
On examining the 11 base substitutions, one was silent, two
nonsense and eight missense. The 1-bp deletion led to aframeshift,
resulting in a stop codon 12 amino acids after the deletion point;
the 4-bp deletion led to a frameshift, again resulting in a stop
codon 36 amino acids after the deletion point; the 19-bp deletion
led to a truncation of six amino acids and a frameshift, which
generated a stop codon 11 amino acids after the deletion point; and
the 3-bp insertion led to a substitution of valine for histidine and
the addition of a serine without producing any frameshift changes.
The 1-bp insertion in patient no. 52 occurs in the intronic region
24 bp before the first nucleotide of exon 5 and does not appear to
affect splicing.
Two ofthe tumours (patient nos. 18 and 52) were found to carry
more than one mutation, and all multiple mutations occurred in
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Table 2 Distribution of GC-AT transitions in the p53 genes in primary lung
tumours, as found in the international database, compared with our results
GC-eAT CpC/GpG CpG Other Total
GC-eAT
Present study 5 (71.4%) 2 (28.6%) - 7
Hollstein et al (1994) 33 (37%) 27 (30%) 29 (33%) 89
Data from cell lines are not included in the above table.
exon 5. In the case ofpatient no. 52, there was an additional 1-bp
insertion in the intronic region, and the distance between the 1-bp
deletion and the C-.T substitution within exon 5 was only four
nucleotides.
Statistical analysis showed no correlation between the presence
ofp53 mutations and the clinicopathological data, i.e. age, stage,
TNM stage, nodes atpathology, alcohol intake, cigarettes and clin-
ical outcome (follow-up 18 months). Samples from 4 of the 18
female patients and 9 of28 male patients containedp53 mutations.
However, p53 mutations occurred more frequently in squamous
cell carcinomas (7 of 18) than in adenocarcinomas (2 of 15), but
this was not statistically significant. Similarly, the presence ofthe
minor allele (Pro) in codon 72 in exon 4, found in 6 out of 46
samples, did not correlate with any of the particular clinicopatho-
logical parameters.
The immunohistochemical study of the p53 protein revealed
that 15 of 45 (33%) samples had negative (-) staining, 5 of 45
(11%) samples had weak positive (+) staining and 25 of45 (56%)
samples had intense positive (++ or +++) staining for p53. We
divided the patients into three classes with respect to the number
of cigarettes they consumed in pack-years: light smokers (0-45
pack-years); moderate smokers (46-67.5 pack-years); and heavy
smokers (76-126 pack-years). A trend was found between p53-
positive staining and the patients' smoking history; however, this
was found to be not statistically significant (P = 0.13) (Table 3).
In the 12 NSCLC specimens withp53 mutations for which we
also hadp53 expression data (Table 1), eight had concomitantp53
mutation and p53-positive staining. However, it is noteworthy that
three of the four tumours containing p53 mutations that had no
p53-positive staining (patient nos. 21, 44 and 52) had mutations
that result in truncation of the expressed protein. The fourth
sample (patient no. 19) has an inframe 3-bp insertion that did not
result in truncation, and so the reason for non-immunoreactivity
remains unclear. It is of interest that patient no. 19 was the only
non-smoker with ap53 mutation.
The TP53 LOH study indicated allelic loss in 9 of38 (23.6%) of
the informative cases. In the case of patient no. 34, microsatellite
instability (MI) was observed at this locus. Statistical analysis
showed no correlation between LOH and the clinicopathological
parameters. However, an inverse correlation was found between
LOH and staining for p53, indicating that overexpression of the
p53 gene was uncommon in samples with LOH at the TP53 locus
(P = 0.005).
In an extensive allelotype analysis of lung tumours, the frac-
tional allele loss (FAL) value was calculated for the 46 tumours for
which we had LOH data for 38 chromosome arms. The FAL value
for this group of tumours was found to be 0.09. (FAL was calcu-
lated as the number ofchromosome arms showing loss ofheterozy-
gosity divided by the number of informative chromosome arms;
Field et al, 1996; Neville et al, 1996.) We investigated whether
Table 3 p53 mutations and overexpression in relation to the smoking history
of the patient
Smoking history p53 mutations p53 overexpression
(packs per day x years
smoking)
0-45 2 11 7 6
46-67.5 5 10 11 4
72-126 4 4 7 1
The patients have been subdivided into light smokers (0-45 pack-years),
moderate smokers (46-67.5 pack-years) and heavy smokers (72-126
pack-years). p53 mutation analysis of light smokers and heavy smokers,
P > 0.05; p53-positive staining analysis of light smokers and heavy
smokers, P = 0.13.
there was a correlation between the presence ofp53 mutations and
the FAL value, but no statistically significant correlation was
found. Furthermore, there was no correlation betweenp53 aberra-
tions and K-ras mutations (Neville et al, 1995a) or allelic loss on
chromosome 9 at 9p23, a site considered to contain a putative
tumour-suppressor gene in these tumours (Neville et al, 1995b).
DISCUSSION
p53 gene inactivation by mutation or allelic loss has been impli-
cated in the development of lung cancer (Greenblatt et al, 1994).
The identification ofmutations that arise within the gene may lead
to an understanding ofthe role ofthep53 gene in the development
oflung tumours and may also help to elucidate the role of certain
carcinogenic agents, e.g. those contained in tobacco or environ-
mental pollutants, in this disease process.
In this study, we found that 28% ofthe tumours contained muta-
tions in the p53 gene. This incidence is significantly lower
(P < 0.0002) than thatreported in a majorreview ofp53 mutations
in 897 lung cancer patients who have smoked (Greenblatt et al,
1994; Hollstein et al, 1994). On comparing our results with those
ofSuzuki et al (1992), who demonstratedp53 mutations in 47% of
30 NSCLCs investigated, no statistically significant difference
was found (P = 0.082). The possibility that p53 mutations were
missed by SSCP screening is very unlikely as SSCP-negative
results were confirmed by sequencing 10 SSCP-negative samples
per exon; however, even if we calculated that 10% of p53 muta-
tions were missed, the total incidence would rise to only 31%,
which is still lower than the average incidence ofp53 mutations in
lung cancer (56%), as reported by Greenblatt et al (1994). Our
results indicate that p53 mutations in NSCLC may be caused by
carcinogens other than those found in tobacco smoke. This may
account for the population-specific mutation spectrum.
Sixty-seven per cent of the NSCLC samples in this study
demonstrated p53-positive staining. It is ofnote that all but one of
the patients' tumours with p53 mutations, excluding those with
insertions or deletions, also demonstrated p53-positive staining.
This provides further evidence for the hypothesis that there is an
increasedp53 gene product in tumours containing mutations in the
p53 gene. The p53-positive staining is considered to represent
stable p53 protein overexpression that results from post-transla-
tional modification and/or p53 protein complexing. However,
there were also NSCLC tumours that demonstrated p53-positive
staining but in which no mutations were found. These differences
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between molecular and immunohistochemical results may be
explained by the possibility that there are mutations in the p53
gene outside exons 4-9, within the p53 promoter region, or that
overexpression ofp53 is not only due top53 mutations but also to
some other factors, e.g. mdm2, which bind to the p53 protein and
thus increase its half-life. Furthermore, it may be argued that the
DO-1 antibody may also detect a stable conformationally altered
wild-type p53 protein which, in its own right, may lead to genetic
instability without an initialp53 mutation.
More than half (6 of 11) of base substitutions occur at G
residues, which is in agreement with previous reports (Greenblatt
et al, 1994). However, in contrast with most previous reports, we
found a higher prevalence of GC-.AT transitions (37.5% of all
mutations) than of GC--TA transversions (12.5%), which would
be expected from a smoking population. Comparison of the ratio
of GC- TA to GC-*AT in this study and Greenblatt's review
showed a significant difference (P = 0.04). Husgafvel-Pursiainen
et al (1995) reviewed the mutational profile in smokers and ex-
smokers among lung cancer patients and found that 34% ofp53
mutations were G-.T base substitutions. In this study, however,
only 18% ofthe smokers had G- T transversions. Findings similar
to our own were reported in NSCLC patients from Taiwan, in
whom G-.T mutations constituted only 6% of p53 mutations
detected in a population sample comprising 61% smokers (Lee et
al, 1994). GC- TA transversions have been attributed to the action
of benzo[a]pyrene, a member of the polycyclic aromatic hydro-
carbons, which represent the major carcinogens found in tobacco
smoke. However, other carcinogens, such as 4-(methylnitro-
samino)-1-(3-pyridyl)-l-butanone (NNK), cause GC-*AT transi-
tions and GC-.TA transversions at CpG and non-CpG sites,
depending on the experimental system used (Wynder and
Hoffmann, 1994). Tobacco smoke is a complex mixture of
compounds, and the mutational spectrum it causes needs further
investigation (DeMarini et al, 1995). Hence, it remains unclear
whether or not the prevalence of GC-.AT transitions found in
the smoking population in this study is a paradox. It is possible
that, rather than one factor acting alone, a combination of one or
many environmental components and genetic factors may act
synergistically.
Strikingly, in this study all four C-*T and one out ofthreeG-.A
mutations (five out of seven GC-.AT in total) occurred at non-
CpG dinucleotides (in this case in CpC/GpG dinucleotides;
Table 2). CpG sites can account for mutations due to spontaneous
deamination of 5-methylcytosine residues, but the reason for the
occurrence ofGC-.AT transitions at non-CpG sites is unclear. As
little is known about methylation at non-CpG sites in mammalian
cells (Tasheva and Roufa 1994), it is uncertain whether GC-.AT
transitions at non-CpG sites represent induced or spontaneous
mutagenesis (Yang et al, 1996).
No correlation was found between the presence of mutations
and the stage of tumour, indicating that p53 mutations may be
considered to play a role in the early development of lung cancer.
However, itmay also be argued thatcells containingp53 mutations
could be harbouring a mutation in another gene that may merely
have a selective growth advantage in vivo, and this would result in
the late amplification of a p53-mutant subset of cells in a mixed-
status tumour cell population. The presence of only one 'non-
smoker' in our samples did not allow us to undertake any
comparison of p53-positive staining and a history of smoking vs
non-smoking; however, a trend was found between p53 immuno-
staining and a history of heavy smoking (76-126 pack-years)
compared with light smoking (0-45 pack-years), but this was
found to be not statistically significant (P = 0.13).
p53 mutations did not correlate with age, alcohol consumption
or prognosis (median 18 months' follow-up). However, a trend
was found between the prevalence ofp53 mutations and squamous
carcinomas, which is in agreement with a previous report by
Mitsudomi et al (1993). The absence of a correlation betweenp53
mutations and various clinicopathological parameters indicates
that a mutation in thep53 gene may notby itselflead to aggressive
cell growth. Recently, an inverse correlation between clinical
outcome and p53-positive immunostaining was found; however,
no correlation was found between p53 mutations and survival
(Carbone et al, 1994). It is also probable that these tumours carry
additional alterations in genes that function as oncogenes or
tumour-suppressor genes; indeed, the allelotype study for this set
oftumours showed a median FAL value of0.09, indicating allelic
imbalance throughout the genome (Neville et al, 1996). In partic-
ular, LOH at the TP53 locus, as shown in this study, was found in
25% ofthese tumours. It is ofnote that only two out often samples
with LOH at TP53 were found to contain a mutation in p53,
implying that another candidate tumour-suppressor gene may also
exist at this locus. Additionally, four mutations in codon 12 ofthe
K-ras gene have also been demonstrated in these tumours (Neville
et al, 1995a). Only one ofthe tumours was found to contain muta-
tions in both the K-ras and thep53 genes.
In conclusion, p53 mutations in the population of the
Merseyside region ofthe UK do not appear to be as common as in
otherreports ofNSCLC. GC-.AT transitions inp53, preferentially
occurring at non-CpG sites, suggest that different environmental
carcinogens may be involved in this geographic area.
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